Johnson & Johnson

News

Lawsuits filed by Bayer in the US are seeking damages and royalties on sales of COVID-19 shots sold by Pfizer/BioNTech, Moderna, and J&J.

News

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

News

J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

A California jury has awarded $40m in damages to two women who sued Johnson & Johnson, claiming that its talc products caused ovarian cancer.

News

J&J's Imaavy has become the first FcRn blocker to be approved in the EU for both adolescent and adult patients with generalised myasthenia gravis.